CN-122012419-A - Type II herpes simplex virus strain HSV-2/KM-1 and application thereof

Abstract

The invention relates to a II type herpes simplex virus strain HSV-2/KM-1 and application thereof, belonging to the technical field of virus microorganism. The II type herpes simplex virus strain HSV-2/KM-1 is preserved in China Center for Type Culture Collection (CCTCC) at the preservation number of V202550 in the year of 2025 and 7 and 25. The II type herpes simplex virus strain HSV-2/KM-1 has cytophilic property and tends to infect genital epithelial cells, and the application of the II type herpes simplex virus strain HSV-2/KM-1 in the detection of neutralizing antibodies of mouse serum reveals the tool role in the immunogenicity evaluation of vaccines. The invention utilizes II type herpes simplex virus strain HSV-2/KM-1 to successfully construct a Hartley guinea pig genital herpes model or a BALB/c mouse genital herpes model, and the models can be used as a novel tool for evaluating HSV-2 vaccine.

Inventors

• SHI JIANDONG
• XIE JIAXIN
• LIN DI
• LI JIXIONG
• QIAN YING
• XU JINGWEN
• ZHANG ZHIDAN

Assignees

• 中国医学科学院医学生物学研究所

Dates

Publication Date

20260512

Application Date

20260414

Claims (4)

1. 1. The II type herpes simplex virus strain HSV-2/KM-1 is characterized in that the II type herpes simplex virus strain HSV-2/KM-1 is preserved in China Center for Type Culture Collection (CCTCC) at a preservation number of V202550 in the 25 th month of 2025.
2. 2. Use of the herpes simplex virus type II strain HSV-2/KM-1 of claim 1 for the construction of a genital herpes model.
3. 3. Use of the herpes simplex II strain HSV-2/KM-1 according to claim 2 for the construction of a genital herpes model, wherein the model is a Hartley guinea pig genital herpes model or a BALB/c mouse genital herpes model.
4. 4. Use of the herpes simplex II strain HSV-2/KM-1 of claim 1 in vaccine evaluation.

Description

Type II herpes simplex virus strain HSV-2/KM-1 and application thereof Technical Field The invention belongs to the technical field of virus microorganisms, and particularly relates to a II type herpes simplex virus strain HSV-2/KM-1 and application thereof. Background Herpes simplex virus type 2 (Herpes Simplex Virus Type, HSV-2) belongs to the genus herpes simplex virus of the subfamily alpha herpes virus of the family herpesviridae, and is an envelope double-stranded DNA virus with the genome length of about 152 kb. HSV-2 is the main cause of genital herpes, its infection rate increases year by year, harfouche et al issue 2020, 13.3% of the world population. Vaccines are the most cost effective means of preventing and treating genital herpes. From the vaccine entering the clinical study stage, BNT163 is a gC2-gD2-gE2 trivalent mRNA vaccine encapsulated in lipid nanoparticles, which has not been completed in the current phase I clinical trial, but is considered to be the vaccine closest to the ideal vaccine based on results on animal models. However, the actual use of the vaccine eventually entails the testing of wild HSV-2 strains for them. Thus, experiments performed with limited laboratory deposits (e.g., HG 52) alone during vaccine development are inadequate, and new clinical isolates that respond to natural infection are an essential evaluation tool for vaccine development. Disclosure of Invention The invention aims to solve the defects of the prior art and provides a II type herpes simplex virus strain HSV-2/KM-1 and application thereof. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: The first aspect of the invention provides a II type herpes simplex virus strain HSV-2/KM-1, wherein the II type herpes simplex virus strain HSV-2/KM-1 is preserved in China center for type culture collection (China center for type culture collection) for 25 days in 2025, and the preservation number CCTCC NO is V202550, and is classified and named as HSV-2/KM-1 Human alphaherpesvirus 2. The second aspect of the invention provides application of the II type herpes simplex virus strain HSV-2/KM-1 in establishing a genital herpes model. Further, the model is a Hartley guinea pig genital herpes model or a BALB/c mouse genital herpes model. The third aspect of the invention provides application of the II type herpes simplex virus strain HSV-2/KM-1 in vaccine evaluation. The invention separates a virus from a patient right buttock herpes secretion sample, and identifies the virus as II type herpes simplex virus by gene sequencing, PCR, immunofluorescence and transmission electron microscope morphological analysis, and the virus is named HSV-2/KM-1. Through transmission electron microscope observation, immunofluorescence, PCR and gene sequencing analysis, the isolated virus is spherical enveloped virus with the wavelength of 100-127nm, the HSV-2 specific gG2 antibody only recognizes the virus, the gene sequence is completely matched with HSV-2, and the HSV-2 virus is determined to be isolated. The full genome comparison of the II type herpes simplex virus strain HSV-2/KM-1 of the invention with 99 strains of viruses which are the most similar to genes in the current GenBank database and the other unique strain of the HSV-2 strain HJ12 from China in the database shows that the HSV-2/KM-1 has the highest overall similarity with the HSV-2 strain in the U.S. from the distribution country, and the closest evolutionarily related to the HSV-2/KM-1 are the MH790606 HSV-2 strain 2015-27216 and the PP099973 HSV-2 isolate 136 in the U.S. from the evolution. According to the invention, two strains 2015-27216, 136 of viruses with the closest evolution relation with HSV-2/KM-1 and a clinical isolate MN187895 HSV-2 isolate HJ12 of China only except HSV-2/KM-1 are selected for genome substitution analysis, so that more specific HSV-2/KM-1 etiology characteristics are obtained from protein level. HSV-2/KM-1 had 27 amino acid substitutions compared to strain 136, 24 amino acid substitutions compared to strain 2015-27216, but 127 amino acid substitutions compared to strain HJ 12. It can be seen that, consistent with the results of the tree analysis, the HSV-2/KM-1 and 136 strains and 2015-27216 strain are far less than HJ12, and these results indicate that the HSV-2/KM-1 has a more intimate relationship with the American strain. Most mutations in HSV-2/KM-1 occurred in ICP4, UL52 and UL36 proteins (amino acid substitutions greater than three residues) compared to strain 136. Wherein, the conservative amino acid substitution is 13, and the polarity change is 14. Compared with the prior art, the invention has the beneficial effects that: The type II herpes simplex virus strain HSV-2/KM-1 has cell tropism and tends to infect genital epithelial cells. Under the same multiplicity of infection (MOI) of the inoculation conditions, HFF-1 cytopathic effect was the fastest among three cells, human non-s